Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care
OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027.
Zacks
Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?
Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase.
Zacks
OCGN's Catalyst Calendar for Trial Data and Filings Through 2028
Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.
Zacks
Ocugen (OCGN) Upgraded to Buy: Here's Why
Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).